The US Food and Drug Administration is concerned that Spectrum Pharmaceuticals Inc. had not begun enrolling patients in a confirmatory trial of its targeted non-small cell lung cancer drug Pozenveo (poziotinib) as of the end of July.
The company is seeking accelerated approval of the drug. FDA said postmarketing studies should be underway at the time of...





